Tag Archives: light activation

Development of thermosensitive liposomes with the help of ML8500

March 13, 2024 by Modulight Content
No comments
Background The proper delivery and release of therapeutic drugs to a specific site or cell type is one of the main challenges in the treatment of diseases. Liposomes, which are vesicles composed of lipids, serve as carriers for drug delivery thanks to their long circulation time. This results to reduced toxicity in healthy tissues and improved therapeutic efficacy of encapsulated drugs. However, conventional liposomes can often be even too stabile, leading to insufficient drug release at the target site. Light activation can offer a solution Continue reading →Customer case Pharmaceutical Nanotechnology led by Professor Timo Laaksonen on controlled drug release and delivery using modern methods and materials. Particular interest lies in using light to both monitor nanomaterial behavior and to trigger e.g. drug release processes. Modulight products: ML8500, ML6600, MLAKIT Prof. Timo Laaksonen Dr. Tatu Lajunen Laser use: Light-triggered drug release studies from light-activated liposomes. ML8500 with 808 nm wavelength was used to induce the release of calcein from liposomes under different temperatures. The effect of different type of lipids on liposomal Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – February 2023

February 23, 2023 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – February 2023 The nomination for Laser-Sharp Research goes to Mäki-Mikola et al. at University of Helsinki for their development of a dynamic cell culturing platform for light-activation studies. The developed platform has a flow chamber connected to a peristaltic pump, which creates a flow that resembles the natural fluid flow at the cell surfaces. ML6500 laser was used to release calcein from liposomes to validate the suitability of the platform for light-triggered drug release. Compared to traditional static cell culture Continue reading →

Treg-Dominant Tumor Microenvironment Is Responsible for Hyperprogressive Disease after PD-1 Blockade Therapy

November 2, 2022 by Modulight Content
No comments
Published in: Cancer Immunology Research Authors: Hiroaki Wakiyama, Takuya Kato, Aki Furusawa, Ryuhei Okada, Fuyuki Inagaki, Hideyuki Furumoto, Hiroshi Fukushima, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi    Published in: Cancer Immunology Research Authors: Hiroaki Wakiyama, Takuya Kato, Aki Furusawa, Ryuhei Okada, Fuyuki Inagaki, Hideyuki Furumoto, Hiroshi Fukushima, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi   Cytotoxic T cells were partially depleted by NIR-PIT (using ML7710 for light activation) in mouse tumor models. PD-1 blockage led to rapid tumor progression compared with controls, indicating that rapid tumor progression, called hyperprogressive disease, after PD-1 blockage therapy can be attributed to imbalance between T cell populations.   Read the article here